Potentiation and priming of platelet activation: a potential target for antiplatelet therapy

Trends in Pharmacological Sciences

Volumn 29, Issue 7, 2008, Pages 352-360

  Gresele, Paolo ^a   Falcinelli, Emanuela ^a   Momi, Stefania ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AF 497; ANTITHROMBOCYTIC AGENT; BATIMASTAT; BEVACIZUMAB; BLOOD CLOTTING FACTOR 8; CD40 LIGAND; CHEMOKINE; CYTOKINE; DG 041; DOXYCYCLINE HYCLATE; ESTRADIOL; GELATINASE A; GROWTH ARREST SPECIFIC PROTEIN 6; HISTAMINE; ILOMASTAT; IMC 1121B; INTERSTITIAL COLLAGENASE; LEPTIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MACROPHAGE DERIVED CHEMOKINE; MARIMASTAT; PD 166793; PEGAPTANIB; PROSTAGLANDIN E2; SOMATOMEDIN C; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUCCINIC ACID; THROMBOPOIETIN; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; VASCULOTROPIN; XL 184; XL 647; XL 880; ZINC;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG TARGETING; HUMAN; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION;

ANIMALS; CD40 LIGAND; DINOPROSTONE; HUMANS; LEPTIN; MATRIX METALLOPROTEINASE 2; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45849092207     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.05.002     Document Type: Article

References (81)

1. Mathers C.D., and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3 (2006) e42
2. Badimon J.J., et al. Pathophysiology of arterial thrombosis. In: Gresele P., et al. (Ed). Platelets in Hematologic and Cardiovascular Disorders - A Clinical Handbook (2008), Cambridge University Press 279-292
3. Lindemann S., and Gawaz M. Platelets and atherosclerosis. In: Gresele P., et al. (Ed). Platelets in Hematologic and Cardiovascular Disorders - A Clinical Handbook (2008), Cambridge University Press 293-307
4. Brass L.F., et al. Novel therapeutic targets at the platelet vascular interface. Arterioscler. Thromb. Vasc. Biol. 28 (2008) s43-s50
5. Forehand J.R., et al. Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst. J. Clin. Invest. 83 (1989) 74-83
6. Chen L.W., et al. Thermal injury-induced priming effect of neutrophil is TNF-alpha and P38 dependent. Shock 26 (2006) 69-76
7. Meldrum D.R., et al. Constructive priming of myocardium against ischemia-reperfusion injury. Shock 6 (1996) 238-242
8. Steenbergen C., et al. Mechanism of preconditioning: ionic alterations. Circ. Res. 72 (1993) 112-125
9. Gresele P., et al. Platelet priming. In: Gresele P., et al. (Ed). Platelets in Hematologic and Cardiovascular Disorders - A Clinical Handbook (2008), Cambridge University Press 53-79
10. Kowalska M.A., et al. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood 96 (2000) 50-57
11. Brass L. Fifty (or more) ways to leave your platelets (in a thrombus). Arterioscler. Thromb. Vasc. Biol. 24 (2004) 989-991
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
13. Bhatt D.L. Intensifying platelet inhibition - navigating between Scylla and Carybdis. N. Engl. J. Med. 357 (2007) 2078-2081
14. Krasopoulos G., et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
15. Snoep J.D., et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154 (2007) 221-231
16. Manfioletti G., et al. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol. Cell. Biol. 13 (1993) 4976-4985
17. Ishimoto Y., and Nakano T. Release of a product of growth arrest-specific gene 6 from rat platelets. FEBS Lett. 466 (2000) 197-199
18. Angelillo-Scherrer A., et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7 (2001) 215-221
19. Nagata K., et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J. Biol. Chem. 271 (1996) 30022-30027
20. Gould W.R., et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J. Thromb. Haemost. 3 (2005) 733-741
21. Angelillo-Scherrer A., et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Invest. 115 (2005) 237-246
22. Burnier L., et al. Plasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjects. J. Thromb. Haemost. 4 (2006) 2283-2284
23. Muñoz X., et al. Association of specific haplotypes of GAS6 gene with stroke. Thromb. Haemost. 98 (2007) 406-412
24. Balogh I., et al. Analysis of Gas6 in human platelets and plasma. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1280-1286
25. Nagase H., et al. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69 (2006) 562-573
26. Sawicki G., et al. Release of gelatinase A during platelet aggregation. Nature 386 (1997) 616-618
27. Sawicki G., et al. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb. Haemost. 80 (1998) 836-839
28. Falcinelli E., et al. Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J. Thromb. Haemost. 3 (2005) 2526-2535
29. Martinez A., et al. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide. Med. Sci. Monit. 7 (2001) 646-651
30. Momi S., et al. Deficiency of matrix metalloproteinase-2 (MMP-2) impairs platelet-dependent haemostasis in mice. J. Thromb. Haemost. 3 Suppl 1 (2005) 1548
31. Momi S., et al. Deficiency of matrix metalloproteinase-2 (MMP-2) protects mice against platelet-dependent thrombosis. Circulation 111 (2004) 229
32. Falcinelli E., et al. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury. Lack of inhibition by aspirin. Br. J. Haematol. 138 (2007) 221-230
33. Falcinelli E., et al. Platelets release matrix metalloproteinases in the coronary circulation of patients with coronary syndromes [abstract]. J. Thromb. Haemost. Suppl 1 (2005) OR370
34. Vasků A., et al. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol. 22 (2004) 585-591
35. Hermann A., et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12 (2001) 74-82
36. Danese S., and Fiocchi C. Platelet activation and the CD40/CD40L ligand pathway: mechanism and implications for human disease. Crit. Rev. Immunol. 25 (2005) 103-121
37. Henn V., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
38. Andre P., et al. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat. Med. 8 (2002) 247-252
39. Prasad K.S., et al. Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12367-12371
40. Anand S.X., et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb. Haemost. 90 (2003) 377-384
41. Lobbes M.B., et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 187 (2006) 18-25
42. Ferrara N. Vascular endothelial growth factor. Eur. J. Cancer 32A (1996) 2413-2422
43. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 358 (2009) 2039-2049
44. Mohle R., et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 663-668
45. Italiano J.E., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111 (2008) 1227-1233
46. Selheim F., et al. Identification of functional VEGF receptors on human platelets. FEBS Lett. 512 (2002) 107-110
47. Weltermann A., et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1757-1760
48. Arisato T., et al. Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region. J. Thromb. Haemost. 1 (2003) 2589-2593
49. Cacciola R.R., et al. Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications. Haematologica 87 (2002) 774-775
50. Sierra-Honigmann M.R., et al. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1686
51. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
52. Elbatarny H.S., and Maurice D.H. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A containing cellular signaling complex. Am. J. Physiol. Endocinol. Metab. 289 (2005) E695-E702
53. 2. Thromb. Haemost. 98 (2007) 1063-1071
54. Konstantinides S., et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 108 (2001) 1533-1540
55. Bodary P.F., et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 287 (2002) 1706-1709
56. Sugiyama C., et al. Platelet aggregation in obese and diabetic subjects: association with leptin level. Platelets 18 (2007) 128-134
57. Gresele P., et al. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol. Sci. 12 (1991) 158-163
58. Vezza R., et al. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 82 (1993) 2704-2713
59. Ma H., et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E2 receptor subtype EP3. Circulation 104 (2001) 1176-1180
60. Fabre J.E., et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Invest. 107 (2001) 603-610
61. Gross S., et al. Vascular-wall produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J. Exp. Med. 204 (2007) 311-320
62. Gresele P., et al. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and non responders. J. Pharmacol. Exp. Ther. 246 (1988) 301-307
63. Davì G., and Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357 (2007) 2482-2494
64. Podrez E.A., et al. Platelet CD36 links hyperlidìpidemia, oxidant stress and prothrombotic phenotype. Nat. Med. 13 (2007) 1086-1095
65. Ohmori T., et al. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2266-2272
66. Chen C., et al. Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1118-1123
67. Nakatani S., et al. Design and synthesis of novel metalloproteinase inhibitors. Bioorg. Med. Chem. 14 (2006) 5402-5422
68. Gao C.Q., et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc. Res. 57 (2003) 426-433
69. Cheung P.Y., et al. Matrix metalloproteinase-2 contributes to ischemia reperfusion injury in the heart. Circulation 101 (2000) 1833-1839
70. Creemers E.E., et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ. Res. 89 (2001) 201-210
71. Hu Y.B., et al. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 9 (2007) 217-229
72. Kuwana M., et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103 (2004) 1229-1236
73. Davis Jr. J.C., et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. 28 (2001) 95-101
74. Otterdal K., et al. Release of soluble CD40 ligand after platelet activation. Studies on the solubilization phase. Thromb. Res. 114 (2004) 167-177
75. Ireson C.R., and Kelland L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 5 (2006) 2957-2962
76. Schenone S., et al. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr. Med. Chem. 14 (2007) 2495-2516
77. Li L.H., et al. Antitumor and antiangiogenic activities of anti-vascular endothelial growth factor hairpin ribozyme in human hepatocellular carcinoma cell cultures and xenografts. World J. Gastroenterol. 13 (2007) 6425-6432
78. Banerjee S., et al. Mechanism of disease: angiogenesis and the management of breast cancer. Nat. Clin. Pract. Oncol. 4 (2007) 536-550
79. Gertler A. Development of leptin anatagonists and their potential use in experimental biology and medicine. Trends Endocrinol. Metab. 17 (2006) 372-378
80. Panicot-Dubois L., et al. Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J. Clin. Invest. 117 (2007) 3708-3719
81. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K{alpha} pathway. Blood 110 (2007) 4243-4252